http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2709680-T3
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ecebc54292ba538ce460b85feded62ec |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7028 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7012 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7012 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
filingDate | 2010-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2019-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a317847665073a6ffbb28a08b6c50d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04f146af0967a8bc2079705509cc90cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bea446622117d5ae2a7713d2d68e693c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_909686413ab8cd6b8c1f66ef81174889 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_987ec26e7bc75c48ba61a009bc524998 |
publicationDate | 2019-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | ES-2709680-T3 |
titleOfInvention | Medicinal carbohydrates for the treatment of respiratory diseases |
abstract | A compound of the pharmaceutically acceptable Formula 1 or Formula 2 wherein Formula (1) has the formula ** Formula ** wherein, R1, R2, R3 are the same or different and each is independently selected from the group consisting of H, CH3, (CH2) nCH3 (n = 1-20), CH2Fenyl, COCR5R6R7 and CO esters; R5, R6, R7 are the same or different and each is independently selected from the group consisting of H, CH3, (CH2) nCH3 (n = 1-20), C6H5, CH2Fenyl and CH3CH2 (OCH2CH2) mCH3 (m = 1- 200); R4 is the same or different from R1, R2, R3 and is selected from the group consisting of H, CH3, (CH2) nCH3 (n = 1-20), CH2Fenyl, COCR5R6R7, CO and R5 'esters, R6' are the same or different and each is independently selected from the group consisting of H or a pharmaceutically suitable inorganic or organic salt, and a pharmaceutically suitable ester; B is H, and A is selected from the group consisting of NHCOCH3, NH2, and NH2 HX, wherein HX represents a pharmaceutically suitable inorganic or organic acid; and wherein Formula (2) has the formula ** Formula ** wherein, R8 is selected from the group consisting of H, CH3, (CH2) nCH3 (n = 1-20), CH2Fenyl, COCH2Fenyl, CO ester and COCR14R15R16; wherein R14, R15, R16 are the same or different and each is independently selected from the group consisting of H, CH3, (CH2) nCH3 (n = 1-20), C6H5, CH2Fenyl, CH2CH2 (OCH2CH2) mCH3 (m = 1-200); citidine, citidine monophosphate, citidine diphosphate, citidine triphosphate, adenosine, adenosine monophosphate, adenosine diphosphate and adenosine triphosphate; R9 is selected from the group consisting of H, CH3, a pharmaceutically acceptable inorganic or organic salt, or a pharmaceutically suitable ester; CH2CR17R18R19 where R17, R18, R19 are the same or different and each is independently selected from the group consisting of H, CH3, (CH2) nCH3 (n = 1-20), CH2CH2 (OCH2CH2) mCH3 (m = 1-200 ), C6H5 and CH2Fenyl; R10, R11, R12 are the same or different and each is independently selected from the group consisting of H, CH3, (CH2) nCH3 (n = 1-20), CH2Fenyl, ester and COCR20R21R22 where R20, R21 and R22 are the same or different and each is independently selected from the group consisting of H, CH3, (CH2) nCH3 (n = 1-20), C6H5, CH2Fenyl, CH2CH2 (OCH2CH2) mCH3 (m = 1-200); R13 is the same or different from R10, R11, R12 and is selected from the group consisting of H, CH3, (CH2) nCH3 (n = 1-20), CH2Fenyl, ester and COCR20R21R22 where R20, where R21, R22 are same or different and each is independently selected from the group consisting of H, CH3, (CH2) nCH3 (n = 1-20), C6H5, CH2Fenyl, CH2CH2 (OCH2CH2) mCH3 (m = 1-200) and R23, R24 they are the same or different and each is independently selected from the group consisting of H, CH3, (CH2) nCH3 (n = 1-20), CH2CH2 (OCH2CH2) mCH3 (m = 1-200), CH2Fenyl, or ester and CH2CR25R26R27 , or pharmaceutically acceptable inorganic or organic salt, and R25, R26, R27 are the same or different and each is independently selected from the group consisting of H, CH3, (CH2) nCH3 (n = 1-20), and C6H5, CH2Fenyl , for use in an amount effective to promote recovery of cell viability in a damaged respiratory cell in a subject affected by a respiratory infection for the treatment of a respiratory condition. |
priorityDate | 2009-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 407.